Health Technology Assessment in Reimbursement Policy of the Slovak Republic

• Autorzy: Tomas Tesar
• Języki publikacji: EN

Abstrakty

EN

Evidence suggests that availability of medicines on the Slovak market is both comprehensive and prompt. The low co-payment rate of reimbursed products results in easy access to highly priced patented products. There is always at least one treatment available in determined therapeutic classes with no co-payment. Evidence suggests that Slovak pharmaceutical expenditures do not result in the most cost effective outcomes. The use of HTA in the decision-making process is vague.(original abstract)

Słowa kluczowe

EN

Health costs; Medical technology; Health care policy

PL

Koszty ochrony zdrowia; Technologia medyczna; Polityka zdrowotna

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2012
• Numer: nr 1
• Strony: 21--23

Twórcy

autor

Tomas Tesar

• UNION health insurance fund, Bratislava, the Slovak Republic

Bibliografia

• Health Data 2010. Paris, Organisation for Economic Co-operation and Development. Available from: http://www.oecd.org; [Accessed: 27 March 2011]
• Szalay T., Pažitný P., Szalayová A., Frisová S., Morvay K., Petrovič M. and van Ginneken E. Slovakia: Health system review. Health Systems in Transition, 2011; 13(2): 1-200
• Kaló Z., Docteur E., Moïse P. Pharmaceutical pricing and reimbursement policies in Slovakia, OECD Health working paper, 2008

Identyfikatory

DOI

10.7365/JHPOR.2012.1.5